ClinicalTrials.gg
CompletedNCT00266656Updated Mar 31, 2017Results posted

Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

A Phase 4 interventional study of Humatrope in Turner Syndrome, sponsored by Eli Lilly and Company. Completed at 9 sites in United States. Open to female participants aged 4 Years to 20 Years. Per ClinicalTrials.gov, last updated 2017-03-31.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
4 Years to 20 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.

Enrollment
9th of 14
69 · median 108
Started
2005
with 2 others
Phase 4
6 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
3 of 14
Eli Lilly and Company

Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 9th largest by enrollment, is one of 3 that started in 2005, is one of 6 in phase 4, and was the 6th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: 4 Years to 20 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing Human Growth Hormone in Turner Syndrome as a file.
02

Study summary

This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome. The main purpose is to determine whether girls who received 2 years of GH treatment before 6 years of age achieve taller adult height than girls who were untreated during this time. The study will also look at middle ear and hearing function, and cognitive and behavioral development. Protocol completion is defined as attainment of height velocity less than or equal to 1.0 cm/year, or bone age greater than or equal to 15 years.

03

Conditions studied

  • Turner Syndrome

Browse trials for

04

Who can participate

Ages eligible
4 Years to 20 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously randomized in study B9R-US-GDFG (NCT00406926)
  • Karyotype-proven Turner syndrome

Exclusion criteria

Exclusion Criteria:

  • Immediate family members of study site personnel directly affiliated with the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Experimental 1 Control

    No drug administration in B9R-US-GDFG (NCT00406926). Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.

    Drug: Humatrope

  • Experimental
    Experimental 2 Humatrope

    Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.

    Drug: Humatrope

Interventions

06

What researchers measure

Primary outcomes

  1. Most Mature Height Standard Deviation Score (SDS)

    SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Baseline through End of Study (10 years)

Secondary outcomes

  1. Height SDS at Various Ages

    SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Age 10, Age 13, Age 16

  2. Age at Attainment of Tanner 2 Breast Development

    The Tanner 2 breast development is the age at first evidence of breast development.

    Time frame: Baseline through End of Study (10 years)

  3. Chronological Age at First Visit Participant Attained Bone Age of 14.5 Years

    Bone age was measured by standard radiograph, x-ray at baseline and annually for 10 years or until attainment of height velocity less than or equal to 1.0 centimeter per year (cm/year) and bone age greater or equal to 15 years.

    Time frame: Baseline through End of Study (10 years)

  4. Reports of Serious Adverse Events

    Number of serious adverse events (SAEs) reported. Any adverse event from this study that results in one of the following outcomes, or is significant for any other reason were reported as an SAE: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a study subject, significant for any other reason (includes cancer, other than superficial, and basal cell or squamous cell carcinomas of the skin, that did not meet other serious adverse event criteria). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through End of Study (10 years)

  5. Percentage of Participants With Occurrence of Pre-specified Clinically Relevant Events

    Percentage of participants for whom certain non-serious, pre-specified adverse events (AEs; those that are commonly observed in Turner syndrome or are known to be related to GH treatment: impaired glucose tolerance, diabetes mellitus, hypothyroidism, benign intracranial hypertension, scoliosis, slipped capital femoral epiphysis, solid tumor/leukemia, pancreatitis, ear infections, and high blood pressure) are reported.

    Time frame: Baseline through End of Study (10 years)

  6. Percentage of Participants With Abnormal Tympanometry Results

    Percentage of participants with abnormal tympanometry \[defined as middle ear dysfunction / middle ear effusion / patent pressure equalizer tube or possible tympanic membrane perforation\] results at baseline, age 10 years, and age 16 years or endpoint.

    Time frame: Baseline, Age 10, Age 16, End of Study (10 years)

  7. Percentage of Participants With Prevalence of Abnormal Audiometry Results

    Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. Prevalence was calculated as number of participants with abnormal hearing divided by number of participants with measurable pure tone audiometry results at that visit.

    Time frame: Baseline, Age 10, Age 16, End of Study (10 years)

  8. Percentage of Participants With Abnormal Audiometry Results Based on Pure Tone Average (PTA)

    Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. PTA is defined as the average of pure tone hearing thresholds at 500, 1000 and 2000 Hz (Hertz), calculated separately for each ear and for each testing method (air or bone); normal PTA is defined as pure tone hearing threshold less than or equal to 20 dB HL (decibels Hearing Level), and abnormal PTA is defined as pure tone hearing threshold greater than 20 DB HL.

    Time frame: Baseline, Age 10, Age 16, End of Study (10 years)

07

Results

Posted Aug 23, 2016

Participant flow

To be included in this study, participants had to be females with karyotype-proven Turner syndrome who were previously randomized in Study B9R-US-GDFG (NCT00406926).

Participant flow — Overall Study
MilestoneEarly TreatedEarly Untreated
Started3633
Completed2220
Not completed1413
Withdrew: Death10
Withdrew: Lost to follow-up41
Withdrew: Withdrawal by subject42
Withdrew: Did not reach final height48
Withdrew: Parent/caregiver decision12

Outcome measures

PrimaryMost Mature Height Standard Deviation Score (SDS)

SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Baseline through End of Study (10 years)
Reported as:
Mean · standard deviation score
Most Mature Height Standard Deviation Score (SDS)
standard deviation scoreEarly TreatedEarly Untreated
Most Mature Height Standard Deviation Score (SDS)-1.37 ± 1.09-1.60 ± 1.21
SecondaryHeight SDS at Various Ages

SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Age 10, Age 13, Age 16
Reported as:
Mean · Standard deviation score
Height SDS at Various Ages
Standard deviation scoreEarly TreatedEarly Untreated
Age 10 (n=32, 30)-0.66 ± 1.16-1.28 ± 1.17
Age 13 (n=29, 29)-1.29 ± 1.24-1.87 ± 1.16
Age 16 (n=18, 18)-1.66 ± 1.11-1.69 ± 1.30
SecondaryAge at Attainment of Tanner 2 Breast Development

The Tanner 2 breast development is the age at first evidence of breast development.

Time frame:
Baseline through End of Study (10 years)
Reported as:
Mean · years
Age at Attainment of Tanner 2 Breast Development
yearsEarly TreatedEarly Untreated
Age at Attainment of Tanner 2 Breast Development11.80 ± 0.2612.14 ± 0.31
SecondaryChronological Age at First Visit Participant Attained Bone Age of 14.5 Years

Bone age was measured by standard radiograph, x-ray at baseline and annually for 10 years or until attainment of height velocity less than or equal to 1.0 centimeter per year (cm/year) and bone age greater or equal to 15 years.

Time frame:
Baseline through End of Study (10 years)
Reported as:
Mean · years
Chronological Age at First Visit Participant Attained Bone Age of 14.5 Years
yearsEarly TreatedEarly Untreated
Chronological Age at First Visit Participant Attained Bone Age of 14.5 Years14.64 ± 0.2515.26 ± 0.23
SecondaryReports of Serious Adverse Events

Number of serious adverse events (SAEs) reported. Any adverse event from this study that results in one of the following outcomes, or is significant for any other reason were reported as an SAE: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a study subject, significant for any other reason (includes cancer, other than superficial, and basal cell or squamous cell carcinomas of the skin, that did not meet other serious adverse event criteria). A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through End of Study (10 years)
Reported as:
Number · events
Reports of Serious Adverse Events
eventsEarly TreatedEarly Untreated
Reports of Serious Adverse Events85
SecondaryPercentage of Participants With Occurrence of Pre-specified Clinically Relevant Events

Percentage of participants for whom certain non-serious, pre-specified adverse events (AEs; those that are commonly observed in Turner syndrome or are known to be related to GH treatment: impaired glucose tolerance, diabetes mellitus, hypothyroidism, benign intracranial hypertension, scoliosis, slipped capital femoral epiphysis, solid tumor/leukemia, pancreatitis, ear infections, and high blood pressure) are reported.

Time frame:
Baseline through End of Study (10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Occurrence of Pre-specified Clinically Relevant Events
percentage of participantsEarly TreatedEarly Untreated
Baseline Ear infections13.918.2
Baseline High Blood Pressure03.0
Baseline Hypothyroidism13.96.1
Baseline Scoliosis22.29.1
Year 1 Ear infections38.939.4
Year 1 High Blood Pressure03.0
Year 1 Hypothyroidism11.112.1
Year 1 Scoliosis16.721.2
Year 2 Diabetes2.80
Year 2 Dilatation of the Aorta03.0
Year 2 Ear infections33.327.3
Year 2 High Blood Pressure03.0
Year 2 Hypothyroidism11.112.1
Year 2 Scoliosis22.224.2
Year 3 Diabetes2.80
Year 3 Dilatation of the Aorta06.1
Year 3 Ear infections30.636.4
Year 3 High Blood Pressure03.0
Year 3 Hypothyroidism11.112.1
Year 3 Scoliosis25.027.3
Year 4 Diabetes2.80
Year 4 Dilatation of the Aorta06.1
Year 4 Ear infections16.730.3
Year 4 High Blood Pressure03.0
Year 4 Hypothyroidism11.112.1
Year 4 Scoliosis25.027.3
Year 5 Diabetes2.80
Year 5 Dilatation of the Aorta06.1
Year 5 Ear infections22.227.3
Year 5 High Blood Pressure03.0
Year 5 Hypothyroidism13.918.2
Year 5 Scoliosis25.027.3
Year 6 Diabetes2.80
Year 6 Dilatation of the Aorta09.1
Year 6 Ear infections19.424.2
Year 6 High Blood Pressure03.0
Year 6 Hypothyroidism13.918.2
Year 6 Scoliosis16.730.3
Year 7 Diabetes2.80
Year 7 Dilatation of the Aorta09.1
Year 7 Ear infections19.418.2
Year 7 High Blood Pressure03.0
Year 7 Hypothyroidism13.915.2
Year 7 Scoliosis13.930.3
Year 8 Diabetes2.80
Year 8 Dilatation of the Aorta2.89.1
Year 8 Ear infections13.918.2
Year 8 High Blood Pressure03.0
Year 8 Hypothyroidism5.612.1
Year 8 Scoliosis13.933.3
Year 9 Dilatation of the Aorta03.0
Year 9 Ear infections2.83.0
Year 9 High Blood Pressure03.0
Year 9 Hypothyroidism2.86.1
Year 9 Scoliosis5.69.1
Year 10 Scoliosis2.80
SecondaryPercentage of Participants With Abnormal Tympanometry Results

Percentage of participants with abnormal tympanometry \[defined as middle ear dysfunction / middle ear effusion / patent pressure equalizer tube or possible tympanic membrane perforation\] results at baseline, age 10 years, and age 16 years or endpoint.

Time frame:
Baseline, Age 10, Age 16, End of Study (10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Tympanometry Results
percentage of participantsEarly TreatedEarly Untreated
Baseline Right Ear44.454.5
Baseline Left Ear47.245.5
Age 10 Right Ear27.815.2
Age 10 Left Ear27.815.2
Age 16 Right Ear2.89.1
Age 16 Left Ear2.83.0
Endpoint Right Ear8.312.1
Endpoint Left Ear11.19.1
SecondaryPercentage of Participants With Prevalence of Abnormal Audiometry Results

Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. Prevalence was calculated as number of participants with abnormal hearing divided by number of participants with measurable pure tone audiometry results at that visit.

Time frame:
Baseline, Age 10, Age 16, End of Study (10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Prevalence of Abnormal Audiometry Results
percentage of participantsEarly TreatedEarly Untreated
Baseline Visit (n=36, 33)52.848.5
Age 10 (n=27, 24)44.429.2
Age 16 (n=7, 9)85.766.7
Endpoint (n=24, 22)37.540.9
SecondaryPercentage of Participants With Abnormal Audiometry Results Based on Pure Tone Average (PTA)

Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. PTA is defined as the average of pure tone hearing thresholds at 500, 1000 and 2000 Hz (Hertz), calculated separately for each ear and for each testing method (air or bone); normal PTA is defined as pure tone hearing threshold less than or equal to 20 dB HL (decibels Hearing Level), and abnormal PTA is defined as pure tone hearing threshold greater than 20 DB HL.

Time frame:
Baseline, Age 10, Age 16, End of Study (10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Audiometry Results Based on Pure Tone Average (PTA)
percentage of participantsEarly TreatedEarly Untreated
Baseline Left Ear Air (n=36, 32)30.631.3
Baseline Left Ear Bone (n=36, 32)2.80.0
Baseline Right Ear Air (n=36, 32)22.237.5
Baseline Right Ear Bone (n=36, 32)22.22.8
Age 10 Left Ear Air (n=27, 21)29.614.3
Age 10 Left Ear Bone (n=27, 21)0.00.0
Age 10 Right Ear Air (n=27, 22)14.818.2
Age 10 Right Ear Bone (n=27, 22)0.09.1
Age 16 Left Ear Air (n=7, 9)57.166.7
Age 16 Left Ear Bone (n=7, 9)0.00.0
Age 16 Right Ear Air (n=7, 9)28.633.3
Age 16 Right Ear Bone (n=7, 9)0.022.2
Endpoint Left Ear Air (n=20, 20)30.035.0
Endpoint Left Ear Bone (n=20, 20)5.020.0
Endpoint Right Ear Air (n=20, 20)20.035.0
Endpoint Right Ear Bone (n=20, 20)10.025.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early Treated—6/36 (16.7%)34/36 (94.4%)
Early Untreated—5/33 (15.2%)32/33 (97%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventEarly TreatedEarly Untreated
ScoliosisMusculoskeletal and connective tissue disorders2/360/33
Anomalous pulmonary venous connectionCongenital, familial and genetic disorders0/361/33
Pterygium colliCongenital, familial and genetic disorders0/361/33
CellulitisInfections and infestations0/361/33
Lobar pneumoniaInfections and infestations0/361/33
PneumoniaInfections and infestations0/361/33
Atrial septal defectCongenital, familial and genetic disorders1/360/33
Gastrointestinal haemorrhageGastrointestinal disorders1/360/33
GastroenteritisInfections and infestations1/360/33
MedulloblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/360/33
Most frequent other events
Showing 10 of 93
Most frequent other events
EventEarly TreatedEarly Untreated
Otitis mediaInfections and infestations9/3612/33
VomitingGastrointestinal disorders12/363/33
PyrexiaGeneral disorders11/368/33
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/369/33
HeadacheNervous system disorders11/369/33
ScoliosisMusculoskeletal and connective tissue disorders7/3610/33
Pharyngitis streptococcalInfections and infestations4/369/33
Orthodontic appliance userSocial circumstances9/367/33
Corrective lens userSocial circumstances3/368/33
NasopharyngitisInfections and infestations8/364/33

Baseline characteristics

All enrolled/started participants.

Age, Continuous
Age, Continuous(years)Early TreatedEarly UntreatedTotal
Mean8.29 ± 1.228.41 ± 1.308.35 ± 1.25
Sex: Female, Male
Sex: Female, Male(Participants)Early TreatedEarly UntreatedTotal
Female363369
Male000
Height
Height(centimeter)Early TreatedEarly UntreatedTotal
Mean124.34 ± 10.08121.06 ± 9.76122.77 ± 9.99
Height Standard Deviation Score (SDS)
Height Standard Deviation Score (SDS)(Standard Deviation Score)Early TreatedEarly UntreatedTotal
Mean-0.84 ± 1.22-1.48 ± 1.23-1.15 ± 1.26
Bone Age
Bone Age(years)Early TreatedEarly UntreatedTotal
Mean8.73 ± 1.558.34 ± 1.578.54 ± 1.56
08

Study locations

9 sites
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital
    Aurora, Colorado 80045, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Children's Hospital of Chicago Research Center
    Chicago, Illinois 60611, United States
  • Riley Hosptial for Children
    Indianapolis, Indiana 46202, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • University of NC at Chapel Hill School of Medicine
    Chapel Hill, North Carolina 27514, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Childrens Hospital and Medical Center
    Seattle, Washington 98105, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2005
First posted
Dec 19, 2005
Start
Dec 2005
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Aug 23, 2016
Last update
Mar 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00266656
Responsible party
Sponsor
First posted
Dec 19, 2005
Start date
Dec 2005
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Aug 23, 2016
Last update
Mar 31, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hrs)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion